Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Note- I only mentioned "trump" to keep cervelo calmer
cheers.
BEST POST OF THE MONTH, LOL!
Amen Newbie. The posts are all about PG being a pig for receiving big salary and not selling the company, nothing else in 2/3 years.
Newbie, just the only thing different is the fact that they are suspending their development of the other stuff, the payroll cutback and the buyback. Lupy is still a mile ahead of the other fading competitors and clearly backed up by EULAR and KDIGO’s position. In my humble opinion, PG knows his tenure is not unlimited and as such he may surprise us suffering investors between now and ASM…jmo.
are you and kiwi one and the same person? don’t be ashamed to admit it, we won’t hold it against you.
Kiwi, what say you on Watson’s take that insurance companies are now realizing that it can be more costly for them in the long run to use other options on LN which eventually will come down to dialysis or transplant in most cases? Using Lupy instead of the other options, believe it or not, can be a cheaper and quality of life extending option for patients and insurance companies. Maybe your wife knows that already but that her hands are tied by her direct or indirect employer…JMO.
Watson. If Lupy (not voc, because voc has just 3 years left on the patent, till 2027) is in the hands of a BP, it could go a long way than LN alone. BP has big pockets to go into different indications for trials( for Lupy, till 2037). They could probably explore SLE and they don’t have to go full monty (just p2 &p3) thus saving them a lot of money and time. Other indications also being treated by cyclosporine could be a target of Lupy since it is a knot or two better than cyclosporine…JMO.
Neutral? You’re already undermining Lupy (‘might be better than Lupy’) with another drug that still has to go on p3 trial. I think you should be comparing it right after the p3 trial is over. Even if p3 is over, it could still NOT be approved by the FDA.
And even if it’s approved, you don’t know yet if it will be effective in the long run(at the least, two years) like Lupy. I know it’s only your opinion but I’m also opining that you’re biased against Lupy from the get go…JMO.
Geez kiwi, you’re promoting another p3 drug? Isn’t that what you intimated on secikumumab p3 trial from Novartis that was discontinued just recently? You were so high up on that drug. Quite a while ago, you were also so high up on Benlysta. I’ll give you an A for effort though.
Not a single competition on the radar screen. The latest one by Novartis was discontinued. This is probably the reason for PG’s intransigence on his stance about the BO price. Honestly, at this time, I couldn’t care less if it’s not bought soon. We have a gem of a drug without any competition in sight , BIC & FIC for this unmet medical need.
Merry Christmas and a happy new to my friends here especially Cervelo, Ho Ho Ho.
So sorry! do you think he’ll haunt us for a thousand years? My bad.
Hehehe, let sleeping dogs lie eh, lol. Anyway, I like what he said about UNCY. I’m tempted about it but if I do, it will just be spare change as he said, money that you can afford to lose and not look back. Ganzie, we’re very close I think here at Auphie land or Auphistan as they call it in central Asia.
Ganz, what he said is true. The stoppage of NVS LN trial adds more oomphs, however infinitely small it is(maybe a quark size, lol) to the BO side. Short story, the news doesn’t hurt us one iota.
Kiwi, thanks for sharing. It’s still low here. You can still get in and perhaps double it quite soon…jmo.
finally you admitted your foolish aria target. Don’t you worry, we’ll rack up some wads of ka ching here, again very soon, just like Aria, unless you didn’t buy back again.
Newbie, hey who knows, maybe the next PR from the management is a request tor the FDA to consider LUPY for SLE This would be the mother of all speculation, lol. It’s a waiting game now, definitely not going down to BR’s fav figure.
Zz, I think you miss #5.
WOW! They don’t even have an approved drug yet. There are two in P3.
“ guess i'll check back in a year.”
I don’t think you can stand not bashing PG & management in one week or two or month. It will be an unbelievable miracle if it happens.
“Simply amazing”, we’re running out of accolades for this guy.
Rumors about Gilead could be true as their collaboration with Galapagos NV on systemic sclerosis treatment is no longer in play since two years ago. Auph drug is proven useful in this indication. Maybe another ka Ching factor in the BO? Hey, who knows….
——————————-
“We are very disappointed not to be able to bring a novel medication to patients suffering from such a devastating disease with high unmet need. We would like to thank the patients and the medical professionals who participated in the ISABELA studies and contributed to the advancement of IPF research. We intend to learn from this data in our continued commitment to develop therapies in IPF and fibrosis,” said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos.
“We are extremely disappointed by this news. Despite this setback, we remain committed to leveraging our novel target research engine and strong cash balance to discover potential therapies for IPF and fibrosis,” said Onno van de Stolpe, CEO of Galapagos.
Ziritaxestat (GLPG1690) is an investigational autotaxin inhibitor discovered by Galapagos. Gilead in-licensed ex-European rights to ziritaxestat in July 2019 and commenced sharing the Phase 3 development costs.
All clinical trials with ziritaxestat, including the long-term extension of the Phase 2a NOVESA trial in systemic sclerosis, will be discontinued.”
LOL! Moose, do you think one of us should just offer him that price for his 1700 shares just so he will leave us alone?
Happy thanksgiving to everybody including the 12.50 guy.
Why do you want to see the results of the tests of a drug from a company managed by Peter GREENLEAF? Are you changing your mind about PG? I tell you, your 1700 shares are in the safe hands of PG.
Otsuka filed NDA for Lupy in Japan.
$AUPH
— LordDragon (@IamLordDragon) November 11, 2023
Otsuka submits NDA—>Japan’s MHLW 👍🏻 pic.twitter.com/umnOw3Ahgv
I guess you’re the only one.
If you have nothing else to do, read this to eliminate boredom…
https://finance.yahoo.com/news/aurinia-pharmaceuticals-announces-presentations-american-160000374.html
I hope your desk doesn’t have a mirror when you wrote this post. Cervelo, life is too short. Give your body some positive vibes the rest of the way. There is not one iota of thing you can do to change Auph destiny, win or lose. Tell your love ones you love them instead of brooding about PG. we’re serious. Your body will appreciate it.
Maximize? That's what his brother said to him. He's now blaming his brother and PG for not cashing at 33.
BR, just wondering whatever happened to our poster here named Benny something. He used to be the most vocal opponent of PG. He is now replaced by another person. I hope he’s still around, honestly.
Ah, we’ve been together through thick and thin and this one is no different, BR. In the end, we always shake our hand. As the Beatles said, “it won’t be long, yeah”.
There’s nowhere to go but up unless it wants to revisit your fav number.
The kind of things that big pharma can do to an upcoming drug like Lupkynis. The potential is staggering. If cyclosporine is in the mix of many immunosuppressive conditions, how much more if Lupy gets recognition, a safer and better alternative.
https://www.drugs.com/drug-class/calcineurin-inhibitors.html
Maybe this(link below) is one of the reasons why PG is hesitant in selling Auph or selling it cheap. It has so much potential. In the link, cyclosporin and Voclosporin were used in the trial for ulcerative colitis yielding similar results but Voclosporin has a better safety profile than cyclosporine. On the other hand, use of cyclosporine A is hampered by significant toxicities including nephrotoxicity, hypertension, dyslipidemia and hyperuricemia. It’s all in the link.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289195/
In my opinion, If only we have unlimited developmental funding like big pharma, this drug will be a novel drug in many immunosuppressive conditions, one in particular is the cytokine storm attacking covid patients during the pandemic when the immune systems of covid patients were in overdrive, the others are conditions treated by cyclosporine. It will go a long way if it is in big pharma’s hand or if we are partnered with them, just my two cents.
Especially days like today, you’re like Nostradamus, Newbie, predicting the manifestation of a rant hours in advance. I get more than a giggle. It’s like a hemorrhoid reacting to a spicy food once it passes the mouth. Sorry, he’ll be here ranting and raving till they closed the shop.
Looks better than Auph at this point.
Kiwi’s wife calls that brain hypoxia